DRDoris Rodríguez-Vidal

Doris Rodríguez-Vidal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Doris Rodríguez-Vidal has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Regular physical activity is associated with lower odds of bodily pain in midlife women

    by Eugenio Arteaga, Juan Enrique Blümel, Alejandra Martinez-Garcia, María Soledad Vallejos, Marcela López, Félix Ayala, Ascanio Bencosme, Andrés Calle, Lucia Costa-Paiva, Maribel Dextre, et al.

    Objective: To evaluate the association between regular physical activity and bodily pain domain of the SF-36 in midlife women, considering pharmacological and physical factors. Methods: This cross-sectional study included 3,523 women aged 40 to 60 years. Participants reported whether they had generalized body pain, physical activity, menopause status, menopause hormone therapy (MHT) use, psychotropic medication use, and comorbidities. Multivariable logistic regression was used to identify independent predictors of bodily pain. Results: Women reporting regular physical activity (n=1806; 56.3%) had 34% lower odds of bodily pain (OR 0.66; 95% CI: 0.58-0.76), independent of BMI, menopause status, psychotropic drug use, and comorbidities. MHT use showed an even stronger association (OR 0.50; 95% CI: 0.41-0.61). Conversely, obesity (OR 1.61; 95% CI: 1.36-1.92), postmenopause status (OR 1.45; 95% CI: 1.26-1.68), psychotropic drug use (OR 1.45; 95% CI: 1.24-1.70), and comorbidities (OR 1.52; 95% CI: 1.31-1.77) were associated with increased pain risk. Conclusions: Regular physical activity is independently associated with lower odds of bodily pain in midlife women. Exercise programs, in combination with MHT, may contribute to optimizing pain management in this population and warrant further prospective investigation.

  • Awareness and clinical impact of the revised FDA warning on menopausal hormone therapy among Latin American physicians. REDLINC XIV

    by Juan E. Blümel, María S. Vallejo, Peter Chedraui, Hugo Salinas, Sócrates Aedo, Alejandra Schüle, Ana L. Ribeiro Valadares, Ascanio Bencosme, Carlos Escalante, Carlos Salinas, et al.

    Objective: To evaluate Latin American physicians’ awareness regarding the recent revised statement of the US Food and Drug Administration (FDA) “black box warning” on menopausal hormone therapy (MHT) and to analyze its self-reported impact on clinical practice. Methods: A multicenter cross-sectional study was conducted in thirteen Latin American countries. Physicians caring for peri- and postmenopausal women completed an anonymous survey assessing awareness of the revised FDA communication, perceived clarity, self-reported impact on clinical practice, and MHT prescribing patterns. Bivariate analyses and multivariable logistic regression were performed. Results: A total of 2,166 physicians participated, mainly obstetrician-gynecologists (75.7%) and endocrinologists (9.0%). Overall, 80.7% were aware of the FDA revised statement. In addition, 90.5% considered that the previous warning had overestimated breast cancer risk, and 78.9% believed that the revised communication provides a more balanced view of risks and benefits. Changes in clinical practice were reported by 59.4% of participants, whereas 18.7% reported increased MHT prescribing. Furthermore, 53.3% modified the way they explain breast cancer risk, and 40.4% reported spending more time on patient education and shared decision-making. Physicians with ≤20 years of professional experience and those from specialties other than obstetrics and gynecology or endocrinology were more likely to report that the FDA revised statement would influence their therapeutic conduct. Conclusions: The revised FDA communication appears to have influenced Latin American physicians’ views and self-reported clinical practice, promoting a more balanced view of MHT and encouraging patient education and shared decision-making. However, the increase in MHT prescribing rates was relatively modest, and overall findings should be interpreted cautiously given the cross-sectional design, self-reported nature of the data, and potential selection bias.


  • Severity of menopausal symptoms is associated with lower work-related quality of life and job satisfaction in midlife Latin American women: REDLINC XIII

    by María S. Vallejo, Juan E. Blümel, Peter Chedraui, Juan Matsumura-Kasano, Paolo Meza, Álvaro Monterrosa-Castro, Mónica Ñañez, Marcela López, Eliana Ojeda, Claudia Rey, et al.


  • Physical activity as an alternative or adjunct to menopausal hormone therapy for symptom management in women with primary ovarian insufficiency

    by Félix Ayala, Juan E. Blümel, María S. Vallejo, Peter Chedraui, Hugo Gutiérrez-Crespo, Marcela López, Juan Matzumura-Kasana, Paolo Meza, Álvaro Monterrosa-Castro, Mónica Ñañez, et al.